Avenna Ltd

Inflammation is an influential factor in various chronic illnesses, such as arthritis and heart disease. Therefore, comprehending the underlying mechanisms is vital in developing effective treatments. Glycomics, which focuses on the study of complex sugars present on cells and proteins, has emerged as a powerful tool in examining the inflammatory process at a molecular level. In this new blog post, Avenna presents a comprehensive overview of how glycomics can be employed to measure chronic inflammation, including cutting-edge technology such as GlyHealth. #technology #glycomics #chronicinflammation #medicalresearch #biotechnology #Avenna #massspectrometry #sugarscience #healthcare #researchblog #molecularbiology

🌟 Advancing Precision Medicine for Rheumatoid Arthritis Patients Avenna is excited to be part of an Innovate UK Grant-funded research feasibility study in collaboration with Personalised (Stratified) Medicine at Ulster University , Ludger Limited and MendezWeiss & Co. Together, we are developing ProVision-RA, long-range prognostic and predictive combination biomarker system. 🎯 What does this mean? ProVision-RA aims to support a precision medicine (PM) approach, enabling more tailored and effective healthcare for patients with Rheumatoid Arthritis (RA). We are particularly focused on the Northern Ireland region, as it currently faces the highest waiting lists to see a specialist across the UK, highlighting a pressing need for innovative solutions in healthcare access and efficiency. 📝 As part of this initiative, we’re conducting surveys to gather insights from RA patients and caregivers in Northern Ireland about diagnosis processes and their daily impact. 💡 Your input can shape the future of RA care—and you could win a small gift for your time! 👉To take part fill in this questionnaire or snap the QR code! https://lnkd.in/gkDQSyxi Join us in making a difference for RA patients in Northern Ireland! #ProVisionRA #PrecisionMedicine #HealthcareResearch #RheumatoidArthritis #NorthernIreland #InnovateUK #multiomics

We’re thrilled to announce that our Project Manager and Patient & Public Involvement Lead, Cindy Weiss, will be speaking at the upcoming “Navigating the Next Era in Pharma Packaging, Labelling and Supply Chain Management” Summit in Barcelona! 🎉 📅 28th–29th November 2024 📍 Venue: Room Mate Carla Hotel, Barcelona Cindy will deliver a presentation titled: "Packaging Solutions for Precision Medicine and Omics Studies in Decentralised Clinical Trials." The talk will highlight our innovative packaging solution designed to: 🔹 Enhance patient engagement and retention. 🔹 Ensure precision and sample integrity for multiomic studies. 🔹 Simplify the experience for participants and researchers. This development reflects our commitment to patient-centered design and advancing clinical trial efficiency in the decentralised trial space. Will you be joining us in Barcelona? Let’s connect! #ClinicalTrials #DecentralisedTrials #PharmaPackaging #PatientEngagement #Innovation #SupplyChainManagement #Packaging #Avenna #PharmaPackagingandSupplyChainConference #Europe #PPSCM Platinum Global Solutions

Excited to share that Nina Skorytchenko, CEO of Avenna, will be speaking at the 9th Annual Clinical Trials Summit in Barcelona! Nina will cover: 🔹 Improving success rates of clinical trials for anti-inflammatory drugs with prognostic and predictive biomarkers for chronic inflammatory diseases (cIDs). 🔹 Current and next-generation biomarkers for Inflammatory Bowel Disease (IBD). 🔹 GlyHealth technology – exploring glycomics as a key precision diagnostics tool. 🔹 Addressing challenges in anti-inflammatory drug development to achieve stronger evidence, better patient selection, and higher approval rates. 📍 Room Mate Carla Hotel, Barcelona 📅 28th–29th November 2024 Don’t miss Nina’s session on how reliable biomarkers are transforming clinical trials and advancing precision medicine. Will you be attending? Let’s connect! #ClinicalTrials #PrecisionMedicine #Biomarkers #Innovation #InflammatoryDiseases #Glycans #GlyHealth

Excited to share that Nina Skorytchenko, CEO of Avenna, will be speaking at the 9th Annual Clinical Trials Summit in Barcelona! Nina will cover: 🔹 Improving success rates of clinical trials for anti-inflammatory drugs with prognostic and predictive biomarkers for chronic inflammatory diseases (cIDs). 🔹 Current and next-generation biomarkers for Inflammatory Bowel Disease (IBD). 🔹 GlyHealth technology – exploring glycomics as a key precision diagnostics tool. 🔹 Addressing challenges in anti-inflammatory drug development to achieve stronger evidence, better patient selection, and higher approval rates. 📍 Room Mate Carla Hotel, Barcelona 📅 28th–29th November 2024 Don’t miss Nina’s session on how reliable biomarkers are transforming clinical trials and advancing precision medicine. Will you be attending? Let’s connect! #ClinicalTrials #Glycans #PrecisionMedicine #Biomarkers #Innovation #InflammatoryDiseases #GlyHealth #CTS

🚀 Driving Scalable Innovation in Clinical Research 🌍 Our CEO, Nina Skorytchenko, recently participated in a thought-provoking panel discussion on "Driving Scalable Innovation That Will Shape the Future of Clinical Research". The session explored cutting-edge technologies that are reshaping the industry and emphasised the critical factors for success. One key takeaway from Nina's insights: Effective communication among all stakeholders from the very beginning is essential. Whether it’s researchers, clinicians, participants, or regulatory bodies, everyone needs to clearly understand the shared goals and the tangible benefits of innovation. Collaboration and transparency lay the foundation for driving meaningful advancements in clinical research. The future of clinical research is here—driven by innovation, technology, and a shared vision of progress. Let’s build it together! 💡 What do you think are the most significant challenges in aligning stakeholders for scalable innovation? Let us know in the comments! ⬇️ #Innovation #ClinicalResearch #FutureOfMedicine #ScalableSolutions #Collaboration #Leadership #GlyHealth #Glycans #ClinicalDataManagmentInnovationEurope2024 #Data2024

Less than 2 weeks to go!

🌟 Recognising Bone and Joint Week 2024 | 12-20 October 🌟 This Bone and Joint Week, Avenna want to highlight the significant impact of musculoskeletal (MSK) conditions. We're dedicated to raising awareness about the physical, emotional, and economic challenges these conditions pose, particularly how they affect mental health and social care systems.   🚀 Introducing ProVision-RA 🚀 We are thrilled to share our success in securing a consortium award with Ludger Limited, Personalised (Stratified) Medicine at Ulster University and MendezWeiss & Co. supported by an Innovate UK grant, to develop ProVision-RA. This project aims to greatly enhance rheumatoid arthritis (RA) diagnostics, and prognosis potentially benefiting over 400,000 people in the UK, including 13,500 in Northern Ireland. ProVision-RA combines different omics and glycomics biomarkers with key indicators to enhance the accuracy of RA diagnostics.   🌐 The Significance of This Week 🌐 Bone and Joint Week is an opportunity to address MSK conditions in their entirety, recognising their potential to drastically alter lives through physical limitations, mental health challenges, and reduced social and work engagement. By promoting more holistic solutions like ProVision-RA, we aim to inspire collaborative efforts and improve patient outcomes.   📚 Learn More About MSK Conditions 📚 If you’re looking to learn more about musculoskeletal disorders such as Rheumatoid Arthritis, we highly recommend exploring the resources available from Versus Arthritis. This outstanding charity provides comprehensive materials that offer invaluable insights and support for those affected by these conditions and their families.   #BoneAndJointWeek #RheumatoidArthritis #PrecisionMedicine #ProVisionRA #MSKAwareness #InnovateUK #HealthcareInnovation #GlyHealth #Glycans #Multiomics #VersusArthritis 

The Avenna team had a pleasure to attend ELRIG UK last week at the ExCeL Arena in London.    We discovered a wide range of topics, from mechanisms of ageing and cell & gene therapy to more practical aspects like advances in assay design, high-content imaging, target identification, and disease modelling.   Did you know that only 5 out of every 100 cancer drugs make it from clinical trials to market? Drug discovery is tough, often involving very high costs (>$4BN) and a low likelihood of success when moving from an initial idea to a marketed drug!   This and more, we have learned during the talk by Cathy Tralau-Stewart Executive Director at Milner Therapeutics Institute. Her insights into the need for a better predictive model resonated with our current work in the field of Inflammatory Bowel diseases. She highlighted the challenge of addressing current limitations in understanding human biology and disease processes. By bridging this gap we can improve the efficiency of drug discovery and speed up translation of innovations into tangible patient outcomes.    Another notable speech was @Professor Arne Akbar of UCL, who shared compelling strategies to enhance immunity during ageing, a vital point to address as we work to improve health outcomes for the ageing population.   Let’s keep pushing the boundaries of what’s possible in drug discovery. If you are developing a drug and looking for complementary or companion diagnostics, get in touch with our team to learn more about our GlyHealth Technology.    #ELRIGDD24 #DrugDiscovery #TranslationalResearch #LifeSciences #Collaboration #Avenna #GlyHealth #Biomarkers

🎉 Exciting News! 🎉 We are delighted to announce that we have been awarded a grant from Innovate UK, part of UK Research and Innovation (UKRI), for our project, ProVision-RA FS. This initiative, taking place in Northern Ireland in partnership with Ulster University, Ludger Limited, and Avenna Ltd, is a feasibility study aimed at developing an innovative, early-warning precision medicine biomarker system to support personalised and proactive treatment for patients with rheumatoid arthritis. We are thrilled about the potential impact this could have on improving patient outcomes. A huge thank you to Innovate UK for their support of this initiative! We look forward to the journey ahead. @UKRI_News Do you or someone you care about live with rheumatoid arthritis? We'd love to hear your experiences and insights. Please feel free to share in the comments or tag this post to spread awareness! #InnovateUK #PrecisionMedicine #RheumatoidArthritis #Biomarkers #HealthcareInnovation #MultiOmic